

The Lancet Oncology journal chooses a PharmaMar poster as one of the most relevant of the ASCO 2018 congress

- **The PharmaMar poster with the data from its trial on small cell lung cancer has been chosen as one of the most relevant by the specialized journal *The Lancet Oncology, July edition***
- **The poster showed the results of the first 61 patients already analyzed, in overall response rate, progression-free survival, overall survival and safety profile**

Madrid, 13th of July 2018.- [The Lancet Oncology](#) magazine has selected, as one of the most relevant, the poster presented by PharmaMar (MSE: PHM) on the trial with lurbinectedin as a single agent for the treatment of small cell lung cancer, presented at the American Society of Clinical Oncology (ASCO) annual meeting recently held in Chicago. In this publication, the prestigious journal reviews the most outstanding advances in oncology that are presented at the congress. The PharmaMar poster has been highlighted for its potential as a new treatment for small cell lung cancer.

The multicenter, phase II trial is assessing the safety and efficacy of lurbinectedin in different solid tumors. Among these, small-cell lung cancer, recurrent after one chemotherapy prior line.

The journal highlights the results of the 61 evaluated patients. An ORR of 39.3% was seen in these patients. Also, the median duration of response was 6.2 months and the median overall survival was 11.8 months.

With respect to the safety profile, the most common adverse event was myelosuppression: 39% of the patients' registered grade 3/4 neutropenia and only 9% had febrile neutropenia. No toxic deaths have been recorded.

The primary endpoint of the study is to measure the overall response rate, also evaluating other secondary objectives such as the duration of response, progression free survival, overall survival, along with the safety profile.

The abstract entitled "*Efficacy and safety of lurbinectedin (PM1183, Zepsyre®) in small-cell lung cancer (SCLC): results from a phase 2 study*" (abstract#8570), presented during the congress is available at:

<https://meetinglibrary.asco.org/record/161909/abstract>

About lurbinectedin

Lurbinectedin is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com